Elixinol Wellness Ltd

As of December 31, 2025, Elixinol Wellness Ltd carries a market capitalization of 1.03M, placing it among publicly traded companies globally. Its enterprise value stands at 2.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Elixinol Wellness Ltd's next confirmed earnings release is scheduled for February 19, 2027.

As of December 31, 2025, Elixinol Wellness Ltd has 413.99M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 0.07, and the price-to-book ratio stands at 0.24.

These figures are as of December 31, 2025. The EV/Sales ratio of 0.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.31M versus a market cap of 1.03M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Elixinol Wellness Ltd maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.99, indicating elevated leverage, while an interest coverage ratio of -13.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Elixinol Wellness Ltd posted a negative return on equity (ROE) of -62.94, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.96, reflecting losses generated across the asset base. Inventory turnover of 2.90 indicates how many times Elixinol Wellness Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Elixinol Wellness Ltd recorded an income tax benefit of -303,944.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -3.43M and -3.12M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Elixinol Wellness Ltd's stock has declined approximately 80.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended December 31, 2025, Elixinol Wellness Ltd generated 8.81M in revenue and converted that into -3.12M in net income, yielding earnings per share of -0.01. EBITDA reached -3.22M, while operating income came in at -3.40M.

As of December 31, 2025, Elixinol Wellness Ltd holds 839,680.80 in cash and equivalents against 2.12M in total debt, resulting in a net debt position of 1.11M. Total book value stands at 4.23M, with working capital of -535,168.68 providing operational flexibility.

These figures cover the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Elixinol Wellness Ltd posted a gross margin of 38.68, reflecting its pricing power and cost economics. The operating margin of -38.61 and net profit margin of -35.48 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -201.04, meaning Elixinol Wellness Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Elixinol Wellness Ltd's most recent stock split took place on December 13, 2024 with a 8:1 split ratio.

As of December 31, 2025, Elixinol Wellness Ltd has an Altman Z-Score of -30.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.